Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for acute heart failure with poor diuretic response or renal impairment
jRCTs031210682Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Acute Heart Failure (AHF) comparing Empagliflozin + usual care with Placebo + usual care (2 arms). Primary endpoint: Hierarchical composite win ratio. Started Sep 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on jRCTs031210682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210682.